In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: CONMED’s current price at $46.72 is substantially below the PERT-weighted fair value of $100.81, indicating significant upside potential supported by diverse valuation methods. High liquidity contrasts with low profitability and efficiency, reflecting operational challenges amid growth prospects. Monte Carlo analysis shows zero downside risk below current price, but high volatility signals elevated uncertainty.